{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116489","form_type":"8-K","ticker":"BGMS","cik":"0001130166","company_name":"Bio Green Med Solution, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.695395+00:00","generated_at":"2026-06-22T00:40:09.989213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cyclacel Q3: net loss $5.1M, cash $23.7M; oral fadraciclib shows 2 partial responses in T-cell lymphoma","bullets":["Cash $23.7M at Sept 30, 2022 (vs $36.6M at Dec 31, 2021); cash runway expected to fund programs to end of 2023.","Oral fadraciclib Phase 1/2: 18 evaluable patients; 2/3 partial responses in T-cell lymphoma, 11 stable diseases across solid tumors.","Oral CYC140 Phase 1/2: no DLTs; durable stable disease at first dose level in ovarian and KRAS G12V NSCLC patients.","Terminating sapacitabine license with Daiichi Sankyo, effective March 23, 2023; not pursuing further development.","Expect to determine RP2D for fadraciclib in 4Q 2022 and start Phase 2 in 1H 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116489","json":"https://secwatch.observer/filing/0001104659-22-116489.json","markdown":"https://secwatch.observer/filing/0001104659-22-116489.md","text":"https://secwatch.observer/filing/0001104659-22-116489.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/0001104659-22-116489-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/tm2230005d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:40:09.989213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e81e69dd59bf1b342e54171a0e3403bd17c6e39","claim":"Bio Green Med Solution, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “ Company ”), dated November 9, 2022, announcing certain financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/0001104659-22-116489-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}